{"name":"Ascendis Pharma Growth Disorders A/S","slug":"ascendis-pharma-growth-disorders-a-s","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxOLVhYTWlpdHV1VUhXZHlNUDdRUnBIdWVCWjVqZ2RSX0J1bEk1ZGxlbkdxcm5OcVhsblduSWFsTklNbXJIdUpZR1A5cm9aQ09QRW1TcTRRS2tnN2dXR2VldHZtSTJ4dFBVRmstUnhndXBPTks2azRBVFlwZEtHbnpzYkY3UkZjUnVEU09jem5ScTdaYkVGY09XRU5weks4TkxxZHQ1RFB2SVJ5YndvN3JEd0VLRlFicEw5Sms5U0lnbnkyWU5wS0ZWbnF0c0x4T0p0aWQxa0Q0dDUta29TWVgtZjJSRzl2aHhHMjlVeGR4RUo2clM0NE8yZG9uTzFHcHhTY3RhdkEzcHVWNEI5TGZtaFZ2YlVUeVFJOE4xOFp1MDRVRzdMckxzRVpSNW4yOTBvN2NaMDc2cmlYeVhPajF4cm5VX0ROVHRJZzVjNEg4Mmo3c1BPdnfSAdsCQVVfeXFMTmpNTDJnTlZhM1FiaXNhWFZNMUkyaHRUY0xiVlRmTUZqODBsZ3hkNWZPUjNmZGV5dHRLNkpHVEo0Q2VOc0RFWERtNENTalNBaFhOWXlNc3ZFMGpGVGdJNUttbzFoVDYyVVdLU1FseUR3RXdPTlJ0LTdNU090Ym1jU0ZnTi1CeUh0NlpsY0ZHSllTN085bWFEUFgtc0IxSjUxZmlaSmstbUtycjJGV3VIZHpFQWhGcU5HcW9PSVI2dTJxSlRIeXNWX3NjQ2ktN1UyX2E0c253ZjRETEZXYUlmS1JoLWhyZjBvandtQVJEYnRrbVZsSkVqNEk0MEt4OGZPOHE2LUxUZm9BYkwtLWoxLUQ1Sm1iV3RPLV94UC1aSENLZTNGN2lDdTVYRjBGaThadXZFWk9kOFg3OE80SFFzWktSY05qVUNTRERxUUd5Nk05ZTRpbEZhUGpVekk?oc=5","date":"2026-04-08","type":"trial","source":"The Manila Times","summary":"New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia - The Manila Times","headline":"New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond L","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNUHdzZnEwWW02RWdBTFNyeDRMMkotT0RzN1RFM3BsN2RCOTFJTFI3UkFseU1Hbmp5QzJKWWRUZjJaZ2daRk44MUZGSkRnZk1vX19CNWh0SjFIbW9ZOFd2MHRyanRYMzJIOHVLVHVOY0U2VVBNeGxYMG15enhpelI2VmV2Z1BlMU1DcWNLTi1MZms5YnJCVjR6VjMtcENWanE1Skhpdm9CVTBuTTZHMC1hbzg1dml2QQ?oc=5","date":"2026-04-07","type":"regulatory","source":"Stock Titan","summary":"YUVIWEL earns FDA orphan exclusivity as Ascendis (ASND) starts U.S. launch - Stock Titan","headline":"YUVIWEL earns FDA orphan exclusivity as Ascendis (ASND) starts U.S. launch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQNGh4dVo1NjlpbklYNV9fTUk5clFWcWxoZ1pEamVPX1FSZmJUdTdLQ2k2enZOMHNyb3dsRnBndzdnMkZ3a0ZFUWZJSk5UYVJmWENMZUpjNUZfNWRyT1hnUkFwRUd1ckJmalhOM2ZlVV93S1FpWXg0dmNDQm9DVE42RXE0bjV5aTZhcWlhdTJCNXI1N3dMWkExSWwycFhvNDZOSDFia1RvejJCZWZnTWN2dHdCbjJiSnU0dGhtZGlOMThQWHVnMUhPajB3X0lGMW1taDZXRGZfcFNDLXc?oc=5","date":"2026-04-07","type":"pipeline","source":"TipRanks","summary":"Ascendis Pharma Secures U.S. Orphan Drug Exclusivity and Launches YUVIWEL for Achondroplasia - TipRanks","headline":"Ascendis Pharma Secures U.S. Orphan Drug Exclusivity and Launches YUVIWEL for Achondroplasia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxQZk5PQXMyS1NBMEt2dGZScHd2bU1kZGN0R28ySWFTWk9kNXlpS3czMWM3ZGhjS1lKOEl0RnEyM3NtTUJUa0F5eFJ6b0ZsT1M5N08xZjBaWDg5d3VxZC1ldWxVZy1ldmJIdFR1eW5aX2hITUh2aGtSOFZ6VWRfNEtOOXBjeFBac2F4bmlFQjJrWnowNUlUYmVidnAzYTFzdGc4dVB2VEttc3F3ci00c3RzV0NuTHRjanh4TjBSSTNXdlJlNkVfdlpsaElxR3BOWXBuc2I0dGg2YlhSUVVFQVNZWnptakZoU3liblNRMkEzTkY0LXdGTzRVdGt0VF9SZw?oc=5","date":"2026-04-06","type":"pipeline","source":"globenewswire.com","summary":"Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States - globenewswire.com","headline":"Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPb1ZKbWVyMWtFMDVRVDNQOERVUWJqOEpwX1BOSkhWY3NTbmVIVm82NGQxdDU5elJQdWZ5UWttR3U3aVNvZU5nV2tPZ09LbXFILVhkZERnV2FKcTVQTGxaVUJmVERlN1Z2S3p5RS11VjdIelpXQlpPX21tVlpqZXNHOG1kZjFpdndNbUpUNlAzYW4waWhwTzZ1b3BySFRJZEd3M0xIUWhQYVEzcjNVNnJWQWJoLXpsNDFf?oc=5","date":"2026-04-06","type":"pipeline","source":"Stock Titan","summary":"First once-weekly growth treatment for achondroplasia reaches U.S. patients - Stock Titan","headline":"First once-weekly growth treatment for achondroplasia reaches U.S. patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNN1FTckxmZ1RxckEyQTBTRU5ndDdQNVA4UnNncjRVMXVqamZLYTI0Znc1aVJTdHRTc2dSR1FCaDhSbHp2SWM3SERDZ001ZHRrTmw4V0VEYXptdTFCb0MySFIzR3NtNzNoOVdmd2FqTnBnRFN1Y1RtTHM3YWhDVDFjeHM2SWxaV3RzYTVyVk9ld0F5X3NKaklsd1VEd1QzRG5EVEdaRGRhYkZmenZaZTU2ajg1OVAybVE3eDNUdkhlWUpNU1FFSG9wNlFaU0JkdThZd1p1S3NQc09OR21Ebkc3Uw?oc=5","date":"2026-03-30","type":"trial","source":"Sahm","summary":"How Investors May Respond To Ascendis Pharma (ASND) Growth‑Disorder Data And New Board Appointment - Sahm","headline":"How Investors May Respond To Ascendis Pharma (ASND) Growth‑Disorder Data And New Board Appointment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOS080ZklzczJVUENmdnZIWlJ6ZnphSlpCdTJEeTlubGxnSFZNblY1MUtLejk3cFgxTTNReFR3UjVUbnh4Y1FRT3VKUlU0cmVsWGhicDZqR3hrV3ozcXZiQW9YQmJVbWZ2WnVWMkk5YzZhcXdjVTg5YmlPZzZEVkF5MVZIOVlId0czczRfSFdOZTNLLTNjN2lJR21za2JKdFE?oc=5","date":"2026-03-03","type":"regulatory","source":"Seeking Alpha","summary":"Ascendis Pharma: Yuviwel Approved Despite Legal Challenges (NASDAQ:ASND) - Seeking Alpha","headline":"Ascendis Pharma: Yuviwel Approved Despite Legal Challenges (NASDAQ:ASND)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNNHhZR19mQVpTMzNFOEQwSmF2eVpfYTFGTHd1MktUaHRHZW9yRW1IdDltSnl5dHZtci00WDZBTnB1QlJfbTJzLXhnazRxdnQxU1lUT0hoVlJOZW9ZQk9udVpxSmxjR0ZrTGtVRTdIdVd3dl9QMnVWWkR4NVc2TW02U0dNbnlzdlFnRXcxRVh4c21fZ1V4OVdVanRFT040dw?oc=5","date":"2026-03-02","type":"regulatory","source":"BioWorld News","summary":"Dwarfism drug gets FDA accelerated approval for Ascendis - BioWorld News","headline":"Dwarfism drug gets FDA accelerated approval for Ascendis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOc01qZW5nVkxqZnd2cUNSeEVlM1dkWFhHQWFqSDZYdVcxSkZ2VE9JYXFzb0RFeVlCTzVJUDBDaVoxWGF5VHdyVjlHVG15WFpBTnN0ZXFydGpRcjAzUkU5aFNEU0JoVF9XWTJZdGFWY0Z3RVpuaXpiY2d2ZjdCN3UydWkzTXdMVnZtYlc2d18tajZvQkRENU53cXd0VmdYZC1OYmFPNGZ6V3JxN1R6Z2xSRGpwVDhEdHkyVmtXbVJZTmpIYTU3d3k1WGo1dWJpd196WVlCRFI4eDQzSUxhM0pXUg?oc=5","date":"2026-01-28","type":"pipeline","source":"ChartMill","summary":"ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum - ChartMill","headline":"ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQRHlPNE1RaW5GcUczTjBYeHdBX1pIdXNzMDkyZFZvRVVPNGNpbS1GOGJBMkdVTVpubUtEMlFub2xpSmVacGxETlNMU0ZJMEZ4S2VaWnhRZ1Y1QUhBMjZzanRCTGFxa3A4dFBzTTJKVGZyOHpOTU8xN2RMbWJkeWEyRG5LNzRFTEMyeG4xS1ByQUJLeWJkdGdHTVVUTEtoV0ZXX1NPZ1RCMFdUWk90dkFXYkx3bXpVc3p4Rl9rdjY2VmJtUnV0cjAxSjd3Q3lMUmFuWGk4SUpkSWhCUDhlVm1sWUxWRVhnSXdsMEZmWg?oc=5","date":"2026-01-07","type":"trial","source":"TipRanks","summary":"Ascendis Pharma Advances Weekly Skytrofa Trial in Pediatric Growth Disorders: What Investors Should Watch - TipRanks","headline":"Ascendis Pharma Advances Weekly Skytrofa Trial in Pediatric Growth Disorders: What Investors Should Watch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE02VmhrZC00ZG04M19lanpyaXdpc1pWdDY4cnotY2RiaU1uR2dPdlBIdTZKVml5aFdVNlVNQWFkRVZCZXVLRjVBMGhiQ3Y5MzdCZTd3b3g5ZHRUUTJBaHBxMkZkY01aTHBw?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Ascendis Pharma A/S (ASND) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Ascendis Pharma A/S (ASND) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNcnZ3Mi1adm9pdTBOZm1BVDlKRE01M1h1NFNDb1NKSmFDMUxoaVlMN2JwUzhBUEZhRmlOV2xDTnY4aUUtbkZ6eGlxcTZjWThrNUFGRS02aF83MkdvU3lvM19odHJJbDFUZ2o2TGNvMnNHd3FrTkhGeDh2V0VOaV9DT0VMNzNsdTlwd0IwM0tOWWpEUFVzck41SU11MU9lS3oxdTRhbFg1UVFsQWRmV3hlOFlxSEwxVTRtYTdV?oc=5","date":"2025-06-02","type":"regulatory","source":"Contemporary Pediatrics","summary":"FDA accepts navepegritide application to treat children with achondroplasia - Contemporary Pediatrics","headline":"FDA accepts navepegritide application to treat children with achondroplasia","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}